Journal article 22680 views
Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry
J. Wagstaff,
R. Jones,
R. Hawkins,
E. Porfiri,
L. Pickering,
A. Bahl,
J. Brown,
S. Buchan,
John Wagstaff
Annals of Oncology, Volume: 27, Issue: 1, Pages: 159 - 165
Swansea University Author: John Wagstaff
Full text not available from this repository: check for access using links below.
DOI (Published version): 10.1093/annonc/mdv504
Abstract
The aim of the RECORD registry was to collect real world data on the outcomes for patients with locally advanced inoperable renal cell carcinoma (RCC) treated with modern targeted therapies. Individual patient data were collected from consecutive patients in one Welsh, one Scottish and five English...
| Published in: | Annals of Oncology |
|---|---|
| Published: |
2015
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa25006 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
The aim of the RECORD registry was to collect real world data on the outcomes for patients with locally advanced inoperable renal cell carcinoma (RCC) treated with modern targeted therapies. Individual patient data were collected from consecutive patients in one Welsh, one Scottish and five English Cancer Centres that treated patients with locally advanced and metastatic RCC. Data from 514 patients were collected between March 2009 and November 2012. Median overall survival (OS) was 23.9 months from the initiation of first line treatment. This is similar to the median OS found in the pivotal registration trials of sunitinib and pazopanib which are the main first line treatments in this disease.Median OS was significantly longer for those patients receiving second line treatment (33 months) compared with those who did not (20.9 months; p=0.008). These data confirm that results in the real world are comparable to results obtained in prospective clinical trials. The data also emphasise the importance of second line therapy in obtaining optimum survival. |
|---|---|
| Keywords: |
Renal Cell Carcinoma, survival, pazopanib, sunitinib |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Issue: |
1 |
| Start Page: |
159 |
| End Page: |
165 |